

# europaean journal of gynaecological oncology

an International Journal

*Editors-in-Chief*

**A. Onnis**                      **P. Bószé**  
*Montréal (Canada)*              *Budapest (Hungary)*

*Associate Editor*

**M. Marchetti**  
*Montréal (Canada)*

*Assistant Editor*

**J. Wilson**  
*San Diego - CA (USA)*

*Editorial Board*

Allen H.H., <i>London, Ontario (Canada)</i>	Geisler H.E., <i>Indianapolis, IN (USA)</i>	Menczer J., <i>Savyon (Israel)</i>
Anteby S.O., <i>Jerusalem (Israel)</i>	Gerbaulet A., <i>Villejuif (France)</i>	Monsonogo J., <i>Paris (France)</i>
Audet-Lapointe P., <i>Montreal (Canada)</i>	Gorins A., <i>Paris (France)</i>	Pinotti A., <i>São Paulo (Brazil)</i>
Ayhan A., <i>Ankara (Turkey)</i>	Heintz A.P.M., <i>Utrecht (The Netherlands)</i>	Piura B., <i>Beer Sheva (Israel)</i>
Balat O., <i>Graziantep (Turkey)</i>	Ioannidou-Mouzaka L., <i>Athens (Greece)</i>	Piver S.M., <i>Buffalo, NY (USA)</i>
Barber H.K., <i>New York, NY (USA)</i>	Jordan J.A., <i>Birmingham, England (UK)</i>	Rakar S., <i>Ljubljana (Slovenia)</i>
Basta A., <i>Krakow (Poland)</i>	Karseladze A.I., <i>Moscow (Russia)</i>	Raju K.S., <i>London, England (UK)</i>
Bender H.C., <i>Dusseldorf (Germany)</i>	Klastersky J., <i>Bruxelles (Belgium)</i>	Shepherd J.H., <i>London, England (UK)</i>
Benedetti Panici P.L., <i>Rome (Italy)</i>	Kubista E., <i>Vienna (Austria)</i>	Stelmachów J., <i>Warsaw (Poland)</i>
Charkviani T., <i>Tbilisi (Georgia)</i>	Kudelka A.P., <i>Houston, TX (USA)</i>	Tjalma W., <i>Antwerpen (Belgium)</i>
De Oliveira C.F., <i>Coimbra (Portugal)</i>	Maggino T., <i>Padua (Italy)</i>	Ungár L., <i>Budapest (Hungary)</i>
Dexeus S. Jr., <i>Barcelona (Spain)</i>	Markowska J., <i>Poznan (Poland)</i>	Vermorken J.B., <i>Edegem (Belgium)</i>
Di Paola G.R., <i>Buenos Aires (Argentina)</i>	Marth C., <i>Innsbruck (Austria)</i>	Vîrtej P., <i>Bucharest (Romania)</i>
Di Re F., <i>Milan (Italy)</i>	Massuger Leon F.A.G., <i>Nijmegen (The Netherlands)</i>	Wang P.-H., <i>Taipei (Taiwan)</i>
Di Saia P., <i>Orange, CA (USA)</i>		Winter R., <i>Graz (Austria)</i>
Fuller A.F. Jr., <i>Boston, MA (USA)</i>		Yokoyama Y., <i>Hirosaki (Japan)</i>

*Publishing Organization (M. Morsani):*

I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)  
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroun-online.com - www.irog.net

*Editorial Office (M. Critelli):*

Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by **CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.**

# European Journal of Gynaecological Oncology

www.irog.net

## General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

### AIMS AND SCOPE

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distinguished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the diffusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

**ANNOUNCEMENTS** regarding meetings, postgraduate courses and symposia will be accepted six months before publication and will be published free of charge.

**BOOK SAMPLES** for review should be sent to the Editorial offices in Montréal or in Padova.

**COPYRIGHT:** the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.

**ADVERTISING INFORMATION:** advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2H3, Tél. 514.4893242-4893640, Fax 514.4854513, E-mail: canlux@mggroup-online.com - www.irog.net

**RESPONSIBILITY:** although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate information, the publisher accepts no responsibility for the consequences of faulty or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.

### SUBSCRIPTION INFORMATION

The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

**Subscriptions are entered with prepayment only.** The annual subscription is \$390 US for Institutions, \$200 US for Individuals. For airmail add \$30, for receipt add \$10 US. Single copy prepaid cost \$95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner's - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. **Only US Funds are accepted.** No bank transfers.

**Claims** for missing issues can be honoured up to six months. **Changes of address:** allow six weeks for all changes to become effective. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and **any communication and requests should be addressed to** I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT.

# European Journal of Gynaecological Oncology

www.irog.net

## Instructions to Authors

### SUBMISSION OF MANUSCRIPTS

Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Storie 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the "Distinguished Expert Series" should be submitted to P. Bószé, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1) 275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers' suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

**Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publication cannot be returned.**

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author's experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and application thereof contained in the Journal. Consult the prescribing information before administering any drug.

### MANUSCRIPT REQUIREMENTS

The Journal follows the "Uniform requirements for manuscripts submitted to biomedical journals" published in the *New England Journal of Medicine* 1991, 324, 424-8 and in the *British Medical Journal* 1991, 302.

Three **manuscripts** typed and double spaced should be submitted by mail (not by email) **with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0.** Manuscripts without an electronic disk will not be accepted. **A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been published or submitted for publication elsewhere.** Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the **Corresponding Author**, responsible for revision and approval of the proofs, should be indicated. **Full-length articles should not exceed 8 printed pages including tables and references.**

After the **title page** (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: **Summary** (purpose of investigation, methods, results, conclusion - about 150 words), **Key words**, **Content** (a 20-word summary), **Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement** (if any), **References, Tables, Legends**.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

**Authors** must give their complete professional identifications and affiliations, including all academic titles and positions.

**Letters to the editor** should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

**Figures:** Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author's name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. **If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).**

**Legends** should be typed on a separate page with Arabic numerals corresponding to the illustrations.

**Tables** should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first citation in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

**References should be numbered consecutively in the order in which they are first mentioned in the text.** Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in *Index Medicus*. The titles of journals should be abbreviated according to the style used in *Index Medicus*.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

**Articles in Journals:** Authors' surname and initials (if more than six names, give six followed by "et al."), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

**Books:** Authors' surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

**Acknowledgments** will be limited to appropriate professionals who were contributors to the paper.

**PROOFS** revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline **the proofs will be considered approved.** Only essential corrections should be made; extensive changes will be charged to the authors.

### BUSINESS MATTERS

The Journal has no commercial advertisements.

**Authors will be expected to contribute to the printing expenses, tables, figures and postage.** For every published article a copy of the Journal will be provided free of charge. **Only payments in US dollars will be accepted.** No bank transfers.

**Reprints** should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.

**DISTINGUISHED EXPERT SERIES**

- Patients with locally advanced cervical cancer should not undergo routine pretreatment surgical staging** 109  
 F. Mota, C. De Oliveira - *Coimbra, PORTUGAL*  
 The state of the art on surgical staging of locally advanced cervical cancer is discussed.

**ORIGINAL ARTICLES**

- Definitive and palliative radiotherapy for cervix cancer in the elderly** 115  
 F.L. Ampil, J.B. Unger, G. Caldito, A. Charrier - *Shreveport, LA (USA)*  
 This retrospective study evaluated the results of radiotherapy for cervical cancer in the elderly who were treated with a definitive or palliative intent.
- Improved survival of patients with ovarian cancer in Northern Denmark, 1985-2004** 119  
 M.S. Tetsche, M. Nørgaard, J. Jacobsen, E.S. Andersen, P. Lundorff, J. Blaakær, H.T. Sørensen - *Boston, MA (USA)*  
 Improvement was seen in the survival of ovarian cancer patients in Northern Denmark between 1985 and 2004.
- Actin bundling protein fascin expression in ovarian neoplasms: Comparison of histopathologic features of tumors obtained by the first and secondary cytoreduction surgeries** 123  
 S. Kabukcuoglu, S.S. Ozalp, U. Oner, K. Bildirici, O.T. Yalcin, T. Oge, E. Colak - *Eskisehir, TURKEY*  
 The aim of the study was to compare the fascin expression pattern and histopathologic features of malign epithelial ovarian tumors obtained by the primary and secondary surgeries.
- Angiopoietin-1, 2 and Tie2 expressions in endometrial adenocarcinoma – the Ang2 dominant balance up-regulates tumor angiogenesis in the presence of VEGF** 129  
 M. Saito, J. Watanabe, T. Fujisawa, Y. Kamata, Y. Nishimura, T. Arai, T. Miyamoto, A. Obokata, H. Kuramoto - *Kanagawa, JAPAN*  
 The Ang2 dominant background up-regulates tumor angiogenesis in the presence of VEGF.
- Prevalence of human papilloma virus infection of the uterine cervix in women with abnormal cervical cytology** 135  
 E. Gonzalez-Bosquet, M.M. Almagro, I. Mora, M. Suñol, J. Callejo, J.M. Lailla - *Barcelona, SPAIN*  
 HPV testing by polymerase chain reaction (PCR) is useful in predicting which patients will present with a high-grade squamous epithelial lesion (HSIL) following biopsy.
- Is there a protective role of progestogens on the proliferation of human ovarian cancer cells in the presence of growth factors?** 139  
 H. Seeger, D. Wallwiener, A.O. Mueck - *Tuebingen, GERMANY*  
 The role of progestogens in the genesis of ovarian cancer remains unclear although a rather protective behaviour has been suggested. Epidemiological studies indicate a possible increase in the risk for combined estrogen/progestin as compared to estrogen alone.
- Oxygenation status of primary and recurrent squamous cell carcinomas of the vulva** 142  
 P. Vaupel, A. Mayer, M. Höckel - *Leipzig, GERMANY*  
 Oxygenation of vulvar cancers is similar to other tumor entities, but does not show more severe hypoxia in recurrent cases. Anemia is associated with a poorer oxygenation status in vulvar cancers, whereas in normal tissue no impact of cHb values on the median pO<sub>2</sub> was observed.
- The incidence of vulvar pathology and vulvectomy within risk and non-risk groups** 147  
 M. Gojnic, V. Dugalic, S. Milicevic, Lj. Arsenijevic, N. Popovic, A. Stefanovic - *Belgrade, SERBIA AND MONTENEGRO*  
 At the Institute of Gynecology and Obstetrics over a period of five years more than 180,000 women were examined; 580 simple and 178 radical vulvectomies were performed.

<b>Survey of adjuvant hormone therapy in patients after endometrial stromal sarcoma</b>	150
O. Reich, S. Regauer - <i>Graz, AUSTRIA</i> The use of adjuvant hormonal therapy in patients with endometrial stromal sarcomas was surveyed.	
<b>Tissue and plasma carcinoembryonic antigen concentration in gynecologic malignancies</b>	153
H. Saygili - <i>Istanbul, TURKEY</i> Tissue and plasma carcinoembryonic antigen concentrations in gynecologic malignancies were studied.	
<b>A study of placental umbilical cord whole blood transfusion in 72 patients with anemia and emaciation in the background of cancer</b>	155
N. Bhattacharya - <i>Calcutta, INDIA</i> A study of placental umbilical cord whole blood transfusion was carried out on cancer patients with anemia and emaciation.	
<b>CASE REPORTS</b>	
<b>Treatment of choriocarcinoma metastases by surgery and polychemotherapy - case report</b>	162
K. Jeremić, M. Gojnic, V. Bošković, R. Argirovic, V. Milenković, J. Jeremić - <i>Belgrade, SERBIA AND MONTENEGRO</i> The clinical picture of choriocarcinoma may vary and is related to the destruction of tissue and bleeding. New chemo protocols containing etoposide, cisplatin and ifosfamide, together with a resection of the focus resistant to chemotherapy, lead in most cases to complete recovery.	
<b>Preoperative breast ultrasound and Doppler velocimetric findings in patients with breast cancer</b>	165
G.M. Mansour, I.K.I. El-Lamie, H.M. El Sayed, A.M. Ibrahim - <i>Cairo, EGYPT</i> Doppler velocimetric assessment of the lateral thoracic artery RI with a cut-off value less than 0.6 may be useful in predicting the malignancy of breast lumps.	
<b>Endometriosis mimicking soft tissue tumors: Diagnosis and treatment</b>	168
A. Marinis, J. Vassiliou, D. Kannas, T.K. Theodosopoulos, A. Kondi-Pafiti, E. Kairi, V. Smyrniotis - <i>Athens, GREECE</i> Clinical manifestation, radiologic appearance and treatment of four women with extragenital endometriosis of the abdominal wall are presented.	
<b>The role of actin bundling protein fascin in the progression of ovarian neoplasms</b>	171
S. Kabukcuoglu, U. Oner, S.S. Ozalp, K. Bildirici, O.T. Yalcin, E. Colak - <i>Eskisehir, TURKEY</i> The aim of the study was to investigate the role of fascin in tumor progression and to investigate its role on endothelial cell migration and angiogenesis in ovarian neoplasms.	
<b>Does raloxifene therapy affect mammographic breast cancer screening in postmenopausal patients?</b>	177
T. Cirpan, F. Akercan, I.M. Itil, G. Gundem, I. Bilgen, M.S. Yucebilgin - <i>Izmir, TURKEY</i> In postmenopausal women with low bone mass, raloxifene therapy for 12 to 16 months did not increase mammographic breast density.	
<b>Gynecologic problems among elderly women in comparison with women aged between 45-64 years</b>	179
S. Ozalp, H.M. Tanir, H. Gurer - <i>Eskisehir, TURKEY</i> Gynecological symptoms and clinical diagnosis on admission of women over 65 and women aged between 45-64 were assessed.	
<b>Histopathologic correlation of dilatation &amp; curettage and hysterectomy specimens in patients with postmenopausal bleeding</b>	182
H. Saygili - <i>Istanbul, TURKEY</i> Histopathologic correlations of dilatation and curettage, and hysterectomy specimens in patients with postmenopausal bleeding were evaluated.	
<b>Retroperitoneal schwannoma presenting as an ovarian tumor</b>	185
F. Tomao, L. Mariani, E. Miele, G.P. Spinelli, S. Tomao - <i>Rome, ITALY</i> A case of a mass in the left adnexal zone discovered in a 56-year-old woman at the Department of General Surgery and diagnosed as ovarian cancer is presented.	
<b>Aggressive angiomyxoma of the vulva: our experience of a rare case with review of the literature</b>	188
M. Varras, C. Akrivis, P. Lekkou, E. Kitsiou, A. Demou, N. Antoniou - <i>Epirus, GREECE</i> The gross histopathologic and immunohistochemic features of a very rare case of aggressive angiomyxoma of the vulva are reported. The international literature is also reviewed.	

<b>Cervical cancer and low-risk HPV; a case report</b>	193
E. Ganzález-Bosquet, A. Muñoz, M. Suñol, J.M. Laila - <i>Barcelona, SPAIN</i>	
A case of cervical cancer in a 32-year-old woman with a genital genotype 6 HPV infection that developed from a low-grade SIL is presented.	
<b>Ovarian hemangioma with elevated CA125 and ascites mimicking ovarian cancer</b>	195
E. Erdemoglu, M. Kamacı, S. Özen, H.G. Şahin, A. Kulusarı - <i>Van, TURKEY</i>	
Ovarian hemangioma may present with ascites and elevated CA-125 and the differential diagnosis from ovarian cancer should be considered.	
<b>A case of primary peritoneal serous papillary carcinoma initially presented by massive bilateral pleural effusions</b>	197
K. Kaira, A. Takise, K. Endou, N. Yanagitani, N. Sunaga, M. Mori - <i>Gunma, JAPAN</i>	
A 76-year-old female nonsmoker with no asbestos exposure who complained of dyspnea during exercise was diagnosed with primary peritoneal serous papillary carcinoma.	
<b>Well differentiated mesothelioma complicating endometrial carcinoma; a case report</b>	200
C. Baykal, P. Arioğlu, M. Gultekin, A. Usubutun, C. Ficicioglu, A. Ayhan - <i>Ankara, TURKEY</i>	
A well differentiated mesothelioma concomitantly seen in an endometrial carcinoma patient is presented.	
<b>Vaginal malignant melanoma in a healthy pregnancy - a case report</b>	201
M. Gojnic, V. Dugalic, S. Milicevic, Lj. Arsenijevic, N. Popovic, A. Stefanovic - <i>Belgrade, SERBIA AND MONTENEGRO</i>	
A case of a patient at the 36 <sup>th</sup> week of gestation who developed vaginal malignant melanoma is presented.	
<b>SHORT REPORT</b>	
<b>CMF with 5-FU in continuous infusion - a pilot study</b>	204
F. Franchi, C. Pastore, P. Seminara - <i>Rome, ITALY</i>	
A pilot study using a revised schedule of CMF with 5-FU in continuous infusion was carried out.	